Search Results

ILiAD Biotechnologies, LLC (ILiAD) reported today that BPZE1, the most advanced next generation pertussis vaccine, demonstrated positive topline interim results in the SUPER (Stand Up to Pertussis) school-age trial conducted in 366 participants in the United Kingdom, Australia and Costa Rica.

Gordian Biotechnology, an in vivo drug discovery and development company, announced its platform that enables patient predictive, in vivo screening of hundreds of gene targets for FDA-recognized diseases of aging at a scale never before possible.

MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

Turn Biotechnologies announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions.

Luxa Biotechnology, a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute in Rensselaer, New York, announced receipt of a $4 million grant from the California Institute for Regeneration Medicine to support the ongoing Phase 1/2a study of RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration.